These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 32398947)

  • 1. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
    Yang S; Wei W; Zhao Q
    Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
    Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3-mediated tumor immunology: Friend or foe?
    Wang L; Kang FB; Shan BE
    Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
    Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
    Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 10. B7 homolog 3 in pancreatic cancer.
    Perovic D; Dusanovic Pjevic M; Perovic V; Grk M; Rasic M; Milickovic M; Mijovic T; Rasic P
    World J Gastroenterol; 2024 Aug; 30(31):3654-3667. PubMed ID: 39193002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
    Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent B7-H3 overexpression in craniopharyngioma.
    Chen C; Wang Y; Zhong K; Jiang C; Wang L; Yuan Z; Nie C; Xu J; Guo G; Zhou L; Yang M; Tong A
    Biochem Biophys Res Commun; 2019 Jun; 514(2):379-385. PubMed ID: 31043272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of B7-H3 in tumors and its potential in clinical application.
    Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 and its role in bone cancers.
    He L; Li Z
    Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.